How David Beckham and a DNA Testing Company Just Disrupted the Entire Wellness Industry

David Beckham and a Hong Kong health-tech company quietly built something that went from zero to $100 million in annualized recurring revenue in 11 months.

Not 11 quarters. Not 11 years. Eleven months.

The product: IM8 a red octagonal container with 92 ingredients in one powder that replaces your entire supplement cabinet.

The company: Prenetics, a publicly-traded health sciences company (NASDAQ: PRE) that pivoted from COVID testing to consumer wellness.

The result: One of the fastest-growing consumer health brands in history, now sold in 30+ countries, with Aryna Sabalenka (world #1 tennis player) as an investor-partner after becoming a fan of the product.

In February 2026, Prenetics sold its remaining non-IM8 assets (including a $70 million stake in Insighta to Tencent) to go all-in on IM8 with $171 million in liquidity and zero debt.

A company that was doing COVID testing 18 months ago just raised more cash than most supplement brands will see in their lifetime and they’re using it to come after AG1, Ritual, and every other premium supplement brand.

Let me show you what’s actually happening here because buried in this story is the blueprint for how to launch a premium consumable brand in 2026, and why the supplement industry is about to have its “Netflix vs. Blockbuster” moment.

The Numbers That Nobody Expected

Let’s start with what makes IM8’s trajectory remarkable:

IM8 Launch to $100M ARR:

• Launch date: Early 2024

• Revenue milestone: $100M+ annualized recurring revenue

• Time to $100M ARR: 11 months

• Countries: 30+ globally

• Price point: $100-140 per month (varies by market)

• Format: All-in-one powder, 92 ingredients

For context, compare to other premium supplement brands:

AG1 (Athletic Greens):

• Founded: 2010

• Time to $100M revenue: ~8 years (hit $100M around 2018)

• Current revenue: $300M+ (2023)

• Time to $100M: 8 years

Ritual:

• Founded: 2016

• Time to $100M revenue: ~6 years (estimated 2022)

• Current revenue: $150M+ (estimated)

• Time to $100M: 6 years

Seed Daily Synbiotic:

• Founded: 2016

• Revenue: ~$100M (2023)

• Time to $100M: 7 years

IM8 hit $100M ARR in 11 months. That’s 7-9x faster than the closest competitors.

How is this possible?

Three reasons that everyone’s missing:

1. David Beckham isn’t just an endorser, he’s co-founder with equity

Unlike typical celebrity supplement deals (5-10% royalty), Beckham is actually building this company. He’s involved in product development, strategic decisions, and has meaningful equity.

His incentive: Build a $1B+ brand, not collect endorsement checks.

2. Prenetics had infrastructure ready to scale from day one

Most supplement startups:

• Raise $5M seed

• Spend 18 months on product development

• Launch DTC-only

• Burn cash trying to scale

• Years to profitability

Prenetics had:

• Public company capital ($171M liquidity post-asset sales)

• Existing supply chain relationships

• Global distribution infrastructure from COVID testing business

• Data/analytics capabilities from DNA testing business

• Launch at scale, profitable from month one

3. Premium all-in-one positioning = higher LTV, lower churn

Traditional supplement brand:

• Sell single-ingredient products ($30-50/month)

• Customer buys from 3-5 brands

• Low switching cost

• Churn: 40-60% annually

IM8 positioning:

• Replace 16+ supplements with one product ($100-140/month)

• Customer consolidates entire routine

• High switching cost (would need to rebuild entire stack)

• Churn: Likely 20-30% annually (estimated based on category leaders)

Lower churn = higher LTV = can afford higher CAC = faster growth.

But here’s what really matters: Prenetics just went all-in.

The Strategic Transformation: From COVID Testing to Consumer Health Empire

Let me show you what Prenetics actually did, because this is one of the most aggressive corporate pivots I’ve seen:

Prenetics Timeline:

2014-2019: DNA Testing Company

• Founded by Danny Yeung (serial entrepreneur, ex-Groupon)

• Focus: Personalized DNA testing for preventive health

• Revenue: Small, venture-scale

2020-2021: COVID Testing Boom

• Pivot to COVID-19 testing during pandemic

• Scale: Processing 40,000+ tests per day at peak

• Revenue: Exploded (exact figures undisclosed, but massive)

• Became one of Asia’s largest COVID testing providers

2022-2023: Public Listing + Strategic Reset

• Listed on NASDAQ (ticker: PRE)

• COVID testing demand declining

• Question: What’s next?

2024: The IM8 Bet

• Launch IM8 with David Beckham as co-founder

• Go hard on premium positioning (not another $30 greens powder)

• Leverage Beckham’s global distribution (500M+ combined social reach)

• Hit $100M ARR in 11 months

2025-2026: The All-In Move

This is where it gets interesting.

Asset sales to fund IM8:

December 2025: Ended Bitcoin Treasury Strategy

• Prenetics had been converting revenue into Bitcoin (bold move)

• Announced end of Bitcoin strategy to focus capital on IM8

• Signal: We’re betting everything on consumer health

February 2026: Sold Insighta stake to Tencent for $70M

• Insighta: Data analytics business (35% stake)

• Buyer: Tencent (one of world’s largest tech companies)

• Proceeds: $70M cash

• Strategic rationale: Exit non-core, fund IM8 global expansion

Also divesting: ACT Genomics and other assets

• ACT Genomics sale: ~$46M (in escrow, $6.3M shown on balance sheet)

• Other non-core assets: Being divested

• Message: It’s IM8 or nothing

Current financial position (February 2026):

• Cash and equivalents: $99.3M

• Financial assets: $29.3M

• Escrow funds: $7.3M ($6.3M ACT + $1M Insighta)

• Alternative assets: $35.2M

• Total adjusted liquidity: $171.1M

• Debt: $0

Prenetics has more cash than most VC-backed consumer brands will raise in their entire existence, zero debt, and one focus: IM8.

Danny Yeung (CEO) said it explicitly:

“Moving forward, it’s just going to be IM8 and bitcoin. A lot of the other stuff we’re looking [to divest]. But if we’re successful in this convergence of health and wealth, then I think that would be something that is like, ‘Oh, wow, you really put health and wealth together.’”

This isn’t diversification. This is all-in.

What Makes IM8 Different (And Why It’s Actually Working)

Most supplement brands fail because they’re “me-too” products with celebrity endorsements.

IM8 is different in five specific ways:

1. The Formula: 92 Ingredients at Clinical Doses (Not Window Dressing)

What most supplements do:

• Include 10-20 ingredients

• Use “fairy dust” doses (too small to be effective)

• Focus on marketing, not formulation

• Example: Many greens powders have 50mg of ingredient that needs 500mg to work

What IM8 does:

• 92 ingredients (vitamins, minerals, adaptogens, probiotics, electrolytes, amino acids)

• Clinical doses (amounts shown in research to be effective)

• Third-party tested (NSF Certified for Sport)

• Full transparency: Manufacturer (VitaQuest) and formula disclosed

Why this matters:

Traditional supplement brand:

• “Our greens powder has 75 ingredients!”

• Doesn’t disclose amounts

• Most ingredients at ineffective doses

• Sounds impressive, doesn’t work

IM8:

• “Our formula has 92 ingredients at clinical doses”

• Full disclosure of amounts

• Third-party tested to verify

• Actually works (based on science, not marketing)

The risk: When you disclose everything, competitors can copy your formula.

IM8’s bet: Brand + distribution + trust will matter more than formula secrecy.

2. The Advisory Board: Actually Credible (Not Just Marketing)

What most supplement brands do:

• Hire influencers as “advisors”

• Maybe one doctor with questionable credentials

• Advisory board is marketing, not oversight

• No real scientific credibility

What IM8 did:

Advisory board includes:

• Researchers from Mayo Clinic (one of world’s top medical centers)

• Scientists from NASA (space nutrition expertise)

• Academic researchers from leading universities

• Medical professionals with actual clinical experience

Why this matters:

When you have Mayo Clinic and NASA scientists on your advisory board, you can’t bullshit the formula.

These people have reputations to protect. They won’t attach their names to garbage.

The result: IM8 has credibility that celebrity supplement brands can’t buy.

3. The Celebrity Structure: Co-Founder, Not Endorser

This is the move that changes everything.

Traditional celebrity supplement deal:

Structure:

• Celebrity licenses name/image

• Gets 5-10% royalty on sales

• Maybe shows up for launch event

• Posts on Instagram 3-4 times

• That’s it

Economics example (traditional):

• Brand revenue: $100M

• Celebrity royalty (8%): $8M

• Celebrity incentive: Post occasionally, collect checks

IM8’s structure with Beckham:

Structure:

• Beckham is co-founder with equity stake (undisclosed %, likely 15-30%)

• Involved in product development (testing formulas, providing feedback)

• Involved in strategic decisions (distribution, partnerships, product roadmap)

• Posts regularly, but also does long-form content, interviews, etc.

• This is his company, not just an endorsement

Economics example (co-founder):

• IM8 valuation at $1B (conservative if trajectory continues)

• Beckham equity (20%): $200M

• Plus board seat, influence over company direction

• Beckham incentive: Build a generational brand

The difference:

Endorsement deal: Make $8M this year, done.

Co-founder deal: Make $200M+ over 5-10 years by building real value.

Beckham is playing the long game. That’s why this works.

4. The Distribution Strategy: Global from Day One

Most DTC brands:

• Launch in US only

• Focus on building US customer base

• Eventually expand internationally (if successful)

• Years to global scale

IM8 launched in 30+ countries simultaneously.

How?

1. Beckham’s global reach:

• 500M+ combined social followers (Beckham + IM8 channels)

• Name recognition in every country

• Instant international distribution via celebrity

2. Prenetics’ existing infrastructure:

• Already operating in Asia (COVID testing, DNA testing)

• Existing supply chain relationships globally

• Regulatory experience (navigating health regulations in multiple countries)

• Infrastructure to support global scale from day one

3. Premium positioning works globally:

• $100-140/month is premium in every market

• Targets same customer globally (health-conscious, affluent, 30-55 years old)

• No need to localize positioning or price point

The result:

Most supplement brands (3 years in):

• Revenue: $50M

• Markets: US + maybe Canada/UK

• Customer base: Regional

IM8 (11 months in):

• Revenue: $100M+ ARR

• Markets: 30+ countries

• Customer base: Global

Global distribution from day one = 3-5x faster scaling.

5. The Subscription Model: High AOV, High Retention

Let’s break down IM8’s unit economics (estimated):

Average order value:

• Price: $100-140 per month (varies by market, let’s use $120)

• Subscription: Monthly delivery

• AOV: $120/month

Customer acquisition cost:

• Beckham’s organic reach (500M followers) = low paid CAC

• Blended CAC (paid + organic): $80-120 (estimated)

• Let’s use $100

Lifetime value (estimated):

• Monthly revenue: $120

• Average subscription length: 12 months (conservative for high-quality all-in-one)

• LTV: $1,440

LTV/CAC ratio:

• LTV: $1,440

• CAC: $100

• Ratio: 14.4x

For comparison:

AG1:

• AOV: $99/month

• CAC: $150-200 (heavily paid marketing)

• LTV: $1,200 (12 months)

• LTV/CAC: 6-8x

Ritual:

• AOV: $30/month

• CAC: $50-80

• LTV: $360 (12 months)

• LTV/CAC: 4.5-7x

IM8’s economics are 2-3x better than competitors because:

1. Higher AOV ($120 vs. $30-99)

2. Lower CAC (Beckham organic reach vs. paid ads)

3. Higher retention (all-in-one vs. single-ingredient)

This is why IM8 hit $100M ARR so fast. The unit economics are exceptional.

The Market Context: Why All-in-One Supplements Are Exploding

IM8 isn’t the first all-in-one supplement. But the category is exploding right now.

Global Dietary Supplements Market:

• Current size: $163B (2024)

• Projected size: $296B (2030)

• CAGR: 10.5%

• Growing fast, but traditional single-ingredient products dominating

All-in-One / Greens Powder Segment:

• Current size: ~$2-3B (estimated, subset of total market)

• Growth rate: 25-35% annually

• Growing 2-3x faster than overall supplements

Why all-in-one supplements are winning:

Consumer problem:

• Average person takes 4-6 supplements daily

• Cost: $100-200/month across multiple brands

• Hassle: Multiple bottles, pills, timing

• “Pill fatigue” is real

All-in-one solution:

• One product replaces everything

• One subscription, one delivery

• Mix with water, done

• Simplicity wins

Category leaders and their approaches:

AG1 (Athletic Greens):

• Positioning: “Comprehensive daily nutrition”

• Price: $99/month

• Formula: 75 ingredients

• Distribution: DTC primarily, some retail

• Revenue: $300M+ (2023)

Huel:

• Positioning: Complete meal replacement

• Price: $60-80/month

• Formula: Macro-focused (protein, carbs, fats) + micronutrients

• Distribution: DTC + some retail

• Revenue: $200M+ (2023)

Ample:

• Positioning: Meal replacement for busy professionals

• Price: $100-130/month

• Formula: Customizable macro/micro blends

• Distribution: DTC only

• Revenue: $20-30M (estimated)

IM8’s positioning vs. competition:

IM8 is the most premium positioning in the category.

They’re not competing on price. They’re competing on:

• Scientific credibility (advisory board)

• Formula comprehensiveness (92 ingredients)

• Celebrity association (Beckham = trust + aspiration)

• Premium perception

This is the luxury play in supplements.

The Risks: What Could Go Wrong

IM8’s growth is impressive, but let’s be realistic about risks:

Risk 1: Celebrity Dependency

The problem:

• Beckham is 50 years old (still relevant, but aging)

• If Beckham’s image suffers (scandal, etc.), IM8 suffers

• Brand too tied to one person

The mitigation:

• Added Aryna Sabalenka (world #1 tennis, female, younger demographic)

• Building scientific credibility independent of Beckham

• Diversifying celebrity association

But: Beckham is still the primary driver. If he exits, brand value drops.

Risk 2: Formula Complexity = Manufacturing Risk

The problem:

• 92 ingredients = complex supply chain

• One ingredient shortage = can’t produce

• Quality control harder with more ingredients

• Manufacturing risk scales with complexity

The mitigation:

• Using VitaQuest (experienced contract manufacturer)

• Third-party testing (ensures consistency)

• But still a risk

Risk 3: Premium Pricing Limits TAM

The problem:

• $120/month limits addressable market

• Only affluent consumers can afford

• TAM smaller than mass-market products

The numbers:

US households that can afford $120/month supplements:

• Household income $150K+: ~20M households

• Willing to spend on premium health: ~30% = 6M households

• TAM: 6M US customers

At 10% penetration:

• Customers: 600K

• Revenue: $864M annually

• This is the ceiling in US alone

Add 30 countries with similar economics:

• Global TAM: ~40M households

• At 5% penetration: 2M customers

• Revenue: $2.9B annually

So the TAM is actually huge, but only if they execute globally.

Risk 4: Competition Intensifying

AG1 (Athletic Greens) is already responding:

• Increased marketing spend

• Celebrity partnerships (Andrew Huberman, Tim Ferriss)

• Product improvements

New entrants launching:

• Wealthy celebrities see IM8’s success

• Expect copycat brands in 2026-2027

• Category getting crowded

IM8’s defense:

• First-mover advantage (established brand)

• Beckham’s unique credibility

• Scientific advisory board

• But competition will eat into growth

Risk 5: Regulatory Scrutiny

The problem:

• Supplement industry is lightly regulated (FDA doesn’t pre-approve)

• Claims must be substantiated

• If IM8 makes aggressive health claims, FDA could intervene

• Regulatory risk exists

IM8’s approach:

• Third-party testing (NSF Certified for Sport)

• Transparent about formula and manufacturing

• Advisory board provides scientific credibility

• Playing it safe, but risk remains

The Path Forward: Can IM8 Become a $1B Brand?

Let’s model IM8’s trajectory:

Current state (February 2026):

• Revenue: $100M+ ARR (11 months in)

• Countries: 30+

• Liquidity: $171M, zero debt

Base case (conservative growth):

Year 2 (2026-2027):

• Revenue growth: 50%

• Revenue: $150M

• Rationale: Distribution expanding, brand awareness growing

Year 3 (2027-2028):

• Revenue growth: 40%

• Revenue: $210M

• Rationale: Entering retail (Target, Whole Foods), international acceleration

Year 4 (2028-2029):

• Revenue growth: 30%

• Revenue: $273M

• Rationale: Maturation, but still strong growth

Year 5 (2029-2030):

• Revenue growth: 20%

• Revenue: $328M

• Rationale: Approaching category leader (AG1 scale)

Valuation at Year 5:

• Revenue: $328M

• Multiple: 4-6x revenue (consumer subscription businesses)

• Valuation: $1.3-2B

Bull case (aggressive growth):

Year 2: $180M (80% growth, product line extensions) Year 3: $324M (80% growth, retail explosion) Year 4: $518M (60% growth, international dominance) Year 5: $777M (50% growth, market leader)

Valuation at Year 5:

• Revenue: $777M

• Multiple: 5-7x (premium for growth)

• Valuation: $3.9-5.4B

Bear case (growth stalls):

Year 2: $130M (30% growth, competition bites) Year 3: $156M (20% growth, churn increases) Year 4: $171M (10% growth, maturation) Year 5: $180M (5% growth, plateau)

Valuation at Year 5:

• Revenue: $180M

• Multiple: 2-3x (slow growth penalty)

• Valuation: $360-540M

Most likely: Between base and bull case.

My estimate: $400-500M revenue by Year 5, $2-3B valuation.

Why?

IM8 has advantages AG1 didn’t have:

• Global distribution from day one

• Celebrity co-founder (not just endorser)

• Public company capital ($171M to deploy)

• Category validation (AG1 proved model works)

But IM8 faces challenges AG1 didn’t:

• More competition (AG1 had clear field)

• Higher price point (limits TAM)

• Celebrity dependency risk

Outcome: IM8 becomes #2 player behind AG1, but at premium positioning with higher margins.

What This Means for Anyone Building Premium Consumer Brands

You don’t need David Beckham or $171M in liquidity to learn from IM8’s playbook:

Lesson 1: Premium Positioning Requires Premium Proof Points

IM8 didn’t just say “we’re premium.”

They proved it:

• Advisory board (Mayo Clinic, NASA)

• Third-party testing (NSF Certified)

• Transparent formula (full disclosure)

• Premium price ($120/month, no apologies)

If you’re charging premium, you need premium proof.

Lesson 2: Celebrity as Co-Founder > Celebrity as Endorser

Equity alignment changes everything.

Endorser (5-10% royalty):

• Posts 3 times, collects checks

• No long-term commitment

• Brand dies when celebrity moves on

Co-founder (15-30% equity):

• Actively builds the business

• Long-term wealth creation

• Brand outlives initial celebrity hype

Structure celebrity partnerships as equity, not royalty.

Lesson 3: All-in-One Positioning = Higher LTV

IM8’s $120/month price point works because they replace $150-200 worth of supplements.

Customer math:

• Before IM8: $150/month across 5 brands

• After IM8: $120/month, one brand

• Savings: $30/month + massive convenience

When you consolidate customer spend, you can charge premium AND save them money.

Lesson 4: Global from Day One (If You Have Infrastructure)

IM8 launched in 30+ countries simultaneously because they had:

• Celebrity with global reach

• Existing operational infrastructure

• Capital to support scale

If you don’t have these, don’t try it.

But if you do, global-first creates 3-5x faster growth than US-only.

Lesson 5: When You Find Product-Market Fit, Go All-In

Prenetics sold $100M+ in assets to focus entirely on IM8.

That’s conviction.

When you find something working, double down. Don’t diversify for safety.

IM8 hit $100M ARR in 11 months. That’s the signal to go all-in, not hedge.

The Final Reality

IM8 went from zero to $100 million in annualized recurring revenue in 11 months.

That’s faster than:

• AG1 (8 years to $100M)

• Ritual (6 years to $100M)

• Almost every venture-backed supplement brand

How?

1. Celebrity co-founder structure (Beckham with equity, not royalty) 2. Premium positioning with proof (Mayo Clinic, NASA, NSF certified) 3. All-in-one replacement strategy (92 ingredients, clinical doses) 4. Global distribution from day one (30+ countries) 5. Exceptional unit economics (LTV/CAC of 14x vs. 6-8x for competitors)

And now Prenetics is going all-in:

• Sold $70M stake to Tencent

• Divesting all non-IM8 assets

• $171M in liquidity, zero debt

• 100% focused on IM8 global expansion

The question isn’t whether IM8 will succeed.

The question is: How big can it get?

Conservative case: $328M revenue, $1.3B valuation by 2030

Bull case: $777M revenue, $5B valuation by 2030

Either way, IM8 is rewriting the playbook on how to launch premium consumer health brands.

And David Beckham the footballer who became a brand is proving that the right celebrity partnership isn’t about endorsements.

It’s about building generational wealth through equity ownership in real businesses.

Are you building a brand that consolidates customer spend, or competing for a slice of it?

Keep building,

David

---

P.S. Danny Yeung (Prenetics CEO) said he has “few, if any, hobbies” and his passion for work is “singular and all-consuming.” He sees the world as “one big case study.” That’s the founder mentality that goes from COVID testing to $100M supplement brand in 18 months. Most founders celebrate exits and retire. Danny sold $100M in assets to go harder on IM8. That’s real conviction.

---

Want to go deeper? Book office hours here - intro.co/DavidOlusegun